CLC7 (CLCN7) Human siRNA Oligo Duplex (Locus ID 1186)

CAT#: SR300850

CLCN7 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each



Need single siRNA in bulk?
Get a free quote

CNY 4,090.00


货期*
4周

规格
    • 1 kit

Product images

经常一起买 (3)
siTran 2.0 siRNA transfection reagent (0.5ml)
    • 500 ul

CNY 2,190.00


Trilencer-27 Fluorescent-labeled transfection control siRNA duplex - 1 nmol
    • 1 nmol

CNY 1,090.00


CLCN7 rabbit polyclonal antibody
    • 100 ul

CNY 1,999.00
CNY 3,280.00

Specifications

Product Data
Purity HPLC purified
Quality Control Tested by ESI-MS
Sequences Available with shipment
Stability One year from date of shipment when stored at -20°C.
# of transfections Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM).
Note Single siRNA duplex (10nmol) can be ordered.
Reference Data
RefSeq NM_001114331, NM_001287
Synonyms CLC-7; CLC7; HOD; OPTA2; OPTB4; PPP1R63
Components CLCN7 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 1186)
Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol
Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml
Summary The product of this gene belongs to the CLC chloride channel family of proteins. Chloride channels play important roles in the plasma membrane and in intracellular organelles. This gene encodes chloride channel 7. Defects in this gene are the cause of osteopetrosis autosomal recessive type 4 (OPTB4), also called infantile malignant osteopetrosis type 2 as well as the cause of autosomal dominant osteopetrosis type 2 (OPTA2), also called autosomal dominant Albers-Schonberg disease or marble disease autosoml dominant. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. OPTA2 is the most common form of osteopetrosis, occurring in adolescence or adulthood. [provided by RefSeq, Jul 2008]
Performance Guranteed OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Customer Reviews 
Loading...